Canntab Therapeutics Limited
CTABF · OTC
2/28/2023 | 11/30/2022 | 8/31/2022 | 5/31/2022 | |
|---|---|---|---|---|
| Revenue | -$0 | $0 | $0 | $0 |
| % Growth | -226% | -54.3% | -2.6% | – |
| Cost of Goods Sold | -$0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | -$0 |
| % Margin | 22.2% | 2.4% | 68.8% | -137.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | -$0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | 1,560.8% | -4,201.6% | -1,977.3% | -2,937.6% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | 1,862.4% | -5,860.7% | -1,214.9% | -3,652.7% |
| EPS | -0.011 | -0.027 | -0.012 | -0.037 |
| % Growth | 60% | -120.8% | 67.7% | – |
| EPS Diluted | -0.011 | -0.027 | -0.012 | -0.037 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | 720.3% | -3,519.7% | -298.2% | -2,642.8% |